CPL409116

DRUG2 trials

Sponsors

Celon Pharma SA

Conditions

HealthyRheumatoid Arthritis

Phase 1

Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers

CompletedNCT04670757

Celon Pharma SAHealthy

Start: 2020-12-08End: 2021-09-08Updated: 2022-05-16

Phase 2

Efficacy and Safety Study Comparing CPL409116 to Placebo in Participants With Active Rheumatoid Arthritis

CompletedNCT05374785

Celon Pharma SARheumatoid Arthritis

Start: 2022-05-01End: 2024-05-27Updated: 2025-01-23

Related Papers

Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial.

2025-06-111 citations

First-in-human study of CPL’116 – a dual JAK/ROCK inhibitor – in healthy subjects

Frontiers in Pharmacology2025-04-011 citations

Monitoramento do Horizonte Tecnológico (MHT) de Inibidores de Janus Quinase (JAKi) para o Tratamento de Artrite Reumatoide

Epidemiologia e Serviços de Saúde2025-01-01